The effects of a novel drug combination on sleep quality in people with sleep apnoea.
- Conditions
- Obstructive sleep apnoeaRespiratory - Sleep apnoea
- Registration Number
- ACTRN12619001427167
- Lead Sponsor
- Flinders University
- Brief Summary
The hypnotic medication (sleeping pill) zolpidem improves sleep efficiency via an increase in the respiratory arousal threshold to counteract potential wake-promoting properties of atomoxetine in people with obstructive sleep apnoea. These changes occur without altering the rate of respiratory events or overnight hypoxaemia (low oxygen levels). However, while the addition of zolpidem does not increase next-day perceived sleepiness, caution is warranted given the potential impact on next-morning objective alertness.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 13
Otherwise healthy men and women with obstructive sleep apnoea
-Adults between 18 to 64 years of age, inclusive
- BMI between 18.5 and 40.0 kg/m2, inclusive
1.History of narcolepsy.
2.Clinically significant craniofacial malformation.
3.Clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery disease or cardiac failure) or hypertension requiring more than 2 medications for control.
4.Clinically significant neurological disorder, including epilepsy/convulsions.
5.History of schizophrenia, schizoaffective disorder or bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders-V (DSM V) or International Classification of Disease tenth edition criteria.
6.History of attempted suicide or suicidal ideation within 1 year prior to screening, or current suicidal ideation.
7.History of clinically significant constipation, gastric retention, or urinary retention, benign prostatic hyperplasia.
8.History of moderate or severe hepatic or renal impairment.
9.History of drug abuse or substance use disorder as defined in DSM-V within 12 months.
10.A significant acute illness or infection requiring medical treatment in the past 30 days.
11.Clinically significant cognitive dysfunction.
12.Untreated narrow angle glaucoma.
13.Women who are pregnant or nursing.
14.Known allergy to any of the study medications.
15.Any medication known to influence breathing, sleep/arousal or muscle physiology.
16.Clausrophobia.
17.Use of medications from the list of disallowed concomitant medications.
18.Treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors, strong cytochrome P450 2D6 (CYP2D6) inhibitors, or monoamine oxidase inhibitors (MAOI) within 14 days of the start of study.
19.Use of another investigational agent within 30 days or 5 half-lives, whichever is longer, prior to dosing.
Other Exclusions
20.<5 hours typical sleep duration.
21.Night- or shift-work sleep schedule.
22.Employment as a commercial driver or operator of heavy or hazardous equipment.
23.Smoking more than 10 cigarettes or 2 cigars per day.
24.Unwilling to use contraception during the study (if relevant).
25.Unwilling to avoid alcohol on the days of the study.
26.Unwilling to limit caffeinated beverage intake (e.g., coffee, cola, tea) to 400 mg/day or less of caffeine, not to be used within 3 hours of bedtime on study days.
27.Any condition that in the investigator’s opinion would present an unreasonable risk to the participant, or which would interfere with their participation in the study or confound study interpretation.
28.Participant considered by the investigator, for any reason, an unsuitable candidate to receive the study medications or unable or unlikely to understand or comply with the study design.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference in sleep efficiency (% total sleep time) between AD036 vs. AD173 measured via polysomnography during each overnight sleep study[Each overnight sleep study (2 single night sleep studies, one on each arm, approximately 1 week wash out between studies)]
- Secondary Outcome Measures
Name Time Method